Managing Dyslipidemia in Chronic Kidney Disease  by Harper, Charles R. & Jacobson, Terry A.
T
(
w
w
b
p
r
t
l
t
t
p
t
t
c
C
A
t
F
P
B
A
S
2
Journal of the American College of Cardiology Vol. 51, No. 25, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
PSTATE-OF-THE-ART PAPER
Managing Dyslipidemia in Chronic Kidney Disease
Charles R. Harper, MD, FACP,* Terry A. Jacobson, MD, FACP*†
Atlanta, Georgia
The incidence of chronic kidney disease (CKD) in the U.S. continues to increase, and now over 10% of the U.S.
population has some form of CKD. Although some patients with CKD will ultimately develop renal failure, most
patients with CKD will die of cardiovascular disease before dialysis becomes necessary. Patients with CKD have
major proatherogenic lipid abnormalities that are treatable with readily available therapies. The severe derange-
ments seen in lipoprotein metabolism in patients with CKD typically results in high triglycerides and low high-
density lipoprotein (HDL) cholesterol. Because of the prevalence of triglyceride disorders in patients with CKD,
after treating patients to a low-density lipoprotein goal, non-HDL should be calculated and used as the secondary
goal of treatment. A review of the evidence from subgroup analysis of several landmark lipid-lowering trials sup-
ports treating dyslipidemia in mild to moderate CKD patients with HMG-CoA reductase inhibitors. The evidence
to support treating dyslipidemia in hemodialysis patients, however, has been mixed, with several outcome trials
pending. Patients with CKD frequently have mixed dyslipidemia and often require treatment with multiple lipid-
lowering drugs. Although statins are the cornerstone of therapy for most patients with CKD, differences in their
pharmacokinetic properties give some statins a safety advantage in patients with advanced CKD. Although most
other lipid-lowering agents can be used safely with statins in combination therapy in patients with CKD, the fi-
brates are renally metabolized and require both adjustments in dose and very careful monitoring due to the in-
creased risk of rhabdomyolysis. After reviewing the safety and dose alterations required in managing dyslipide-
mia in patients with CKD, a practical treatment algorithm is proposed. (J Am Coll Cardiol 2008;51:2375–84)
© 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.025d
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dhe incidence and prevalence of chronic kidney disease
CKD) is increasing in the U.S. (1,2). Although some patients
ith CKD will ultimately develop renal failure, most patients
ith CKD will die of cardiovascular disease before dialysis
ecomes necessary (3). Patients with CKD have major
roatherogenic lipid abnormalities that are treatable with
eadily available therapies, yet many clinicians are reluctant to
reat these patients aggressively, citing concerns about safety or
ack of evidence suggesting clinical benefit when using drugs in
his population (4). We will briefly review the staging of CKD,
he epidemiology of cardiovascular disease (CVD) in the CKD
opulation, and the characteristics of the dyslipidemia found in
hese patients. We will then review the evidence concerning
reating the dyslipidemia, followed by a discussion of safety
onsiderations and treatment strategies.
lassification of Severity of CKD
ccording to the National Kidney Foundation (NKF), 1 of
he following 2 characteristics is required before a patient is
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chering-Plough.m
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008, accepted March 4, 2008.iagnosed with CKD: 1) kidney damage for 3 months, as
onfirmed by biopsy or markers of damage such as mi-
roalbuminuria with or without a decrease in glomerular
ltration rate (GFR); or 2) GFR 60 ml/min/1.73 m2 for
3 months (5). In individuals with CKD, staging is based
n the GFR (Table 1). Patients with stage I CKD have a
ormal GFR accompanied by proteinuria or other markers
f kidney damage. Stage II, or mild, CKD is diagnosed
hen the GFR is 60 to 89 ml/min/1.73 m2. Patients with
tage III, or moderate, disease have a GFR of 30 to 59
l/min/1.73 m2, and severe disease (stage IV) is diagnosed
s a GFR of 15 to 29 ml/min/1.73 m2. Overt kidney failure,
r CKD stage 5, is defined as a GFR 15 ml/min/1.73 m2.
he prevalence of stage 5 CKD (kidney failure or hemodi-
lysis) is 0.1% of the U.S. population, and the prevalence of
ild to severe disease (CKD stages 1 to 4) is 11% of the
.S. population (5).
pidemiology of Cardiovascular
isease in Patients With CKD
emodialysis patients (stage 5 CKD) have extremely high
orbidity and mortality from CVD. Based on data from the
.S. Renal Data System Coordinating Center Case-Mix
dequacy Study, the prevalence of clinical coronary heart
isease (CHD) in hemodialysis patients is 40%, and CVD
ortality is 10 to 30 times higher than in the general
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by gender, age, race, and the
presence of diabetes (6).
The aging of the U.S. popula-
tion and the epidemic of diabetes
have greatly increased the inci-
dence of mild to moderate CKD
in the U.S. A prospective
population-based study of sub-
jects 65 years old followed pa-
tients with CKD for an average
of 7 years; CKD, defined as cre-
atinine 1.5 mg/dl in men and
1.3 mg/dl in women, was
found in 11% of participants (7).
Those with CKD were more
likely to develop CVD, conges-
tive heart failure, or peripheral
vascular disease (Table 2) (8).
This relationship persisted after
adjusting for traditional risk fac-
tors, including age. Similar find-
ngs were reported in the Atherosclerosis Risk in Commu-
ities Study, which demonstrated that a decreasing GFR
as independently associated with the development of
therosclerotic CVD (9).
The link between dyslipidemia and increased CVD risk in
atients with CKD has been difficult to establish in large part
ue to the myriad other cardiovascular risk factors observed in
atients with CKD, including increased oxidative stress, in-
ammation, physical inactivity, anemia, vascular calcification,
ndothelial dysfunction, and reduced nitric oxide availability.
pidemiologic studies have suggested that hemodialysis pa-
ients with higher total cholesterol levels have lower mortality;
owever, these findings are not statistically significant when
orrected for inflammation and nutrition (10,11).
haracteristics of Dyslipidemia in CKD
KD causes profound dysregulation of lipoprotein metabo-
ism, resulting in multiple lipoprotein abnormalities (Table 3)
12). Dyslipidemia develops during the early stages of CKD,
nd significant changes in apolipoproteins usually precede
hanges in plasma lipid levels (13,14). Depressed high-
Abbreviations
and Acronyms
CHD  coronary heart
disease
CKD  chronic kidney
disease
CVD  cardiovascular
disease
CYP-3A4  cytochrome
p450-3A4
GFR  glomerular filtration
rate
HDL-C  high-density
lipoprotein cholesterol
LDL-C  low-density
lipoprotein cholesterol
MI  myocardial infarction
NKF  National Kidney
Foundation
NLA  National Lipid
Association
Stages of Chronic Kidney Disease
Table 1 Stages of Chronic Kidney Disease
Stage Description
1 Kidney damage with normal or increased GFR
2 Kidney damage with mildly decreased GFR
3 Moderately decreased GFR
4 Severely decreased GFR
5 Kidney failureAdapted from Sarnak et al. (5).
GFR  glomerular filtration rate.ensity lipoprotein (HDL) levels and increased triglyceride-
ich lipoproteins are the major lipid abnormalities.
Reductions in plasma concentrations of apoprotein
Apo)A-I and ApoA-II are thought to play a large role in
he low HDL cholesterol (HDL-C) levels. ApoA-I and
poA-II are mandatory components of the HDL particle.
atients with CKD have been shown to have reduced
enetic expression of these apoproteins at sites of HDL
roduction in the liver (15). Another factor contributing to
ow HDL-C levels is the profound inflammation present in
hese patients. Chronic inflammation results in decreased
lbumin levels. Albumin serves as a carrier of free choles-
erol from the peripheral tissues to HDL, and a reduction in
lbumin may contribute to reduced HDL-C levels (12).
The increased plasma triglyceride levels can be explained
n part by significant increases in plasma ApoC-III levels.
poprotein C-III is a potent inhibitor of the enzyme
ipoprotein lipase, which is responsible for the degradation
f triglyceride-rich particles (16). Numerous other factors
ontribute to the increased triglycerides observed in patients
ith CKD, and a comprehensive description is beyond the
cope of this review.
vidence Concerning Treatment in
emodialysis Patients (CKD Stage 5)
lthough hemodialysis patients have excessive risk of mor-
idity and mortality from CVD, the evidence concerning
reatment of hemodialysis patients with lipid-modulating
rugs is equivocal. There is observational evidence suggest-
ng a benefit from treating dyslipidemia in patients on
emodialysis. In the U.S. Renal Data System Dialysis
orbidity and Mortality Study, 3,700 patients on hemodi-
lysis were followed for 2 years. Statin users had a 32%
GFR,
min/1.73 m2
U.S. Prevalence,
Thousands
U.S. Prevalence,
%
90 5,900 3.3
60–89 5,300 3.0
30–59 7,600 4.3
15–29 400 0.2
5 or dialysis 300 0.1
ardiovascular Event Rates* in 2000 and 2001
Table 2 Cardiovascular Event Rates* in 2000 and 2001
Group AMI CVA/TIA PVD ASVD Death
Nondiabetes/non-CKD 1.6 7.6 6.9 14.1 5.5
Diabetes/non-CKD 3.2 13.1 12.8 25.3 8.1
Nondiabetes/CKD 3.9 16.6 19.9 35.7 17.7
Diabetes/CKD 6.9 22.0 26.6 49.1 19.9
dapted from Foley et al. (8). *Rates are reported for 100 patient-years.
AMI  acute myocardial infarction; ASVD  atherosclerotic vascular disease; CKD  chronic
idney disease; CVA/TIA  cerebrovascular accident/transient ischemic attack; PVD  peripheral
ascular disease.ml/
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June 24, 2008:2375–84 Treatment of Dyslipidemia in CKDelative risk reduction in total mortality, whereas fibrate
sers had no reduction in cardiovascular or total mortality
17). In another observational study, the Dialysis Outcomes
ractice Patterns Study, 9,800 hemodialysis patients were
ollowed for 5 years, and statin users had a 31% (p 
.0001) relative risk reduction in total mortality compared
ith nonusers (18).
The 4D trial (Die Deutsche Diabetes Dialyse Studie) is
he only prospective randomized controlled clinical trial
ith statins in a hemodialysis population (Table 4) (19). A
otal of 1,200 type II diabetics on hemodialysis participated
n this study and were randomized to atorvastatin 20
g/day or placebo for 4 years. In stark contrast to the
bservational data, atorvastatin 20 mg/day had a nonsignif-
cant 8% relative risk reduction (95% CI 0.77 to 1.10; p 
.37) on the combined primary end point of cardiac death,
onfatal myocardial infarction (MI), or stroke. Further-
ore, atorvastatin increased the risk of fatal stroke (RR
.03; 95% CI 1.05 to 3.93; p 0.04). In both the treatment
nd the control groups, 21% of the cardiac deaths were due
o MI, whereas 59% were attributed to sudden cardiac death
19). This suggests that dysrhythmia may be an important
ause of cardiovascular deaths in hemodialysis patients, and
hat this cause of death may not be modifiable with a statin.
nother explanation for these negative results is that the 4D
tudy population had atherosclerosis that was so advanced,
atients were beyond obtaining benefit from drug therapy.
hese patients had been on dialysis for at least 2 years, 50%
ere smokers, and 50% had a prior history of MI.
The OPACH (Omega-3 Fatty Acids as Secondary Pre-
ention Against Cardiovascular Events in Patients Who
ndergo Chronic Hemodialysis) study was a recent ran-
omized, double-blind, placebo controlled trial in 206
hronic hemodialysis patients (20). Participants were ran-
echanisms ofyslipidemia in Chronic Kidney Disease
Table 3 Mechanisms ofDyslipidemia in Chronic Kidney Disease
Protein Change Effect on Plasma Lipids or LP
ApoA-1 2 2 HDL
LCAT 2 2 HDL-C, HDL-2/HDL-3
CETP 1 2 HDL-C
ACAT 1 1 VLDL-C,2 HDL-C
LPL 2 1 Trig (1 delipidation of VLDL and CM)
VLDL receptor 2 1 VLDL, Trig
Hepatic lipase 2 1 IDL, CM remnants, HDL-TG, Trig, LDL-TG
LRP 2 1 IDL, CM remnants
ApoCII/CIII ratio 2 1 Trig (1 LPL activity)
Pre- HDL 1 1 Trig (1 LPL activity)
dapted from Vaziri (4).
2  decreases; 1  increases; ACAT  acyl-CoA (cholesterol acyl) transferase; Apo 
poprotein; CETP  cholesterol ester transferase protein; CM  chylomicron; DGAT  acyl-CoA
iglycerol acyl transferase; HDL  high-density lipoprotein; HDL-C  high-density lipoprotein
holesterol; HDL-TG high-density lipoprotein triglyceride; IDL intermediate-density lipoprotein;
CAT  lecithin cholesterol acyl transferase; LDL-TG  low-density lipoprotein triglyceride; LP 
ipoproteins; LPL  lipoprotein lipase; LRP  low-density lipoprotein receptor-related protein; Trig
triglyceride; VLDL  very-low-density lipoprotein; VLDL-C  very-low-density lipoprotein choles-
erol; VLDL-TG  very-low-density lipoprotein triglyceride.omized to 1.7 g/day of omega-3 fatty acids administered as ecapsules of omega-3-acid ethyl esthers (eicosapentaenoic
cid 45% and docosahexaenoic acid 37.5%) or an olive oil
lacebo. Although no significant reduction was seen in the
ombined primary end point of cardiovascular events or
eath (62 events in the omega-3 group and 59 in the control
roup), there was a 70% (95% CI 0.10 to 0.92; p  0.036)
elative risk reduction in MI. In addition, the incidence of
dverse events was not significantly greater than placebo.
his trial was limited by the small number of participants
nd the small changes in lipoproteins seen during the trial.
There are 2 large randomized trials underway that may
elp to answer the question concerning the use of statins in
emodialysis patients. The AURORA (A Study to Evaluate
he Use of Rosuvastatin in Subjects on Regular Hemodial-
sis: an Assessment of Survival and Cardiovascular Events)
rial is a randomized placebo controlled trial with 2,700
emodialysis patients using rosuvastatin 10 mg/day (21). In
nother ongoing trial, the SHARP (Study of Heart and
enal Protection) trial, there will be an arm of the study
ith 3,000 hemodialysis patients randomized to simvastatin
0 mg/day or simvastatin 20 mg/day plus ezetimibe (22).
vidence Concerning Treatment in Patients
ith Mild to Moderate CKD (CKD Stages 1 to 4)
n patients with earlier stages of CKD there are data derived
rom the subgroup analysis of several landmark secondary
revention trials (Table 4). The Heart Protection Study
nrolled 20,000 British men and women age 40 to 80 years
ho were at increased risk of death from CVD due to
iabetes, coronary heart disease (CVD), or other atheroscle-
otic disease (23). This 5-year study evaluated the benefit of
owering cholesterol with simvastatin 40 mg/day. The
rimary outcomes were total mortality and fatal and non-
atal vascular events. This large study population included a
ubgroup of 1,329 patients with CKD with creatinine
anging from 1.3 to 2.3 mg/dl. There was a relative risk
eduction of 28% (95% CI 0.72 to 0.85; p  0.05). The
vent rate was 39.2% in the control group and 28.2% in the
imvastatin arm, yielding an absolute risk reduction (ARR)
f 11% and a number needed to treat of 9. This ARR is
emarkable compared with the ARR of 5.4% for the entire
eart Protection Study population.
In the CARE (Cholesterol and Recurrent Events) study,
ver 4,000 patients with previous MI and plasma total
holesterol 240 mg/dl were randomized to pravastatin 40
g/day or placebo and followed for approximately 5 years
Table 4). A subgroup of 1,700 patients with creatinine
learance 75 ml/min was evaluated. These patients with
ild CKD had a 28% (95% CI 0.55 to 0.95; p  0.02)
elative risk reduction and a 4% ARR in the primary end
oint (death from coronary disease or symptomatic nonfatal
yocardial infarction) when treated with pravastatin 40
g/day (24).
The only published prospective randomized clinical trialvaluating statin therapy in patients with mild CKD is the
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Treatment of Dyslipidemia in CKD June 24, 2008:2375–84REVEND IT (Prevention of Renal and Vascular End
tage Disease Intervention Trial) (Table 4) (25). In this
rimary prevention trial with a 2  2 factorial design, 864
atients with microalbuminuria were randomized to fosino-
ril 20 mg/day or matching placebo and to pravastatin 40
g/day or matching placebo. Participants were followed for
years. Pravastatin 40 mg/day resulted in a nonsignificant
3% reduction (0.87 [95% CI 0.49 to 1.57]; p  0.649) in
he primary end point of cardiovascular mortality and
ospitalization for cardiovascular morbidity. This study was
imited, because it was statistically underpowered due to the
nusually small number of cardiovascular events in the study
opulation.
The ALERT (Assessment of Lescol in Renal Transplant
rial) was a randomized double-blind placebo-controlled
rial in 2,102 renal transplant recipients (Table 4). Partici-
ants had a mean baseline low-density lipoprotein choles-
erol (LDL-C) of 160 mg/dl and mean serum creatinine of
.6 mg/dl (26). In this 5-year trial, randomization to
uvastatin 40 to 80 mg/day resulted in a nonsignificant 17%
isk reduction (p  0.139) in the combined primary end
oint of cardiac death, nonfatal MI, or coronary interven-
ion procedures. This trend toward benefit was demon-
trated without any increase in graft loss or renal dysfunc-
ion. A subsequent analysis of the ALERT trial using
ardiac death and nonfatal MI as the primary end point
emonstrated a statistically significant 35% risk reduction
ipid-Modulating Clinical Trials in Patients With Chronic Kidney Dis
Table 4 Lipid-Modulating Clinical Trials in Patients With Chroni
Study Population Design P
Statin trials
4D (19) n  1,255, diabetics on
hemodialysis
RCT Card
s
s
PREVEND IT
(25)
n  1,439, microalbuminuria,
GFR 60
RCT, 2  2 factorial
design
CV m
h
HPS (23) n  1,329, Cr 1.3–2.3, CHD,
diabetes, or other occlusive
arterial disease
RCT subgroup, 2  2
factorial design
Ove
v
CARE (24) n  1,711, CHD, GFR 75
ml/min
Post-hoc subgroup of
RCT
CHD
s
ALERT (26) n  2,102, renal transplant
recipients
RCT Card
c
Nonstatin trials
VA-HIT (28) n  1,046, men with CHD,
CrCl 75 ml/min
Post-hoc subgroup of
RCT
Coro
OPACH (20) n  206, hemodialysis
patients with CHD
RCT Tota
d
RR  absolute risk reduction; CHD  coronary heart disease; Cr  serum creatinine; CrCl 
olyunsaturated fatty acids; NA  not applicable; NFMI  nonfatal myocardial infarction; RCT p  0.005) (27). mIn the nonstatin, VA-HIT (Veterans’ Affairs High-
ensity Lipoprotein Intervention Trial), over 2,500 men
ith CHD were enrolled and randomized to gemfibrozil
,200 mg/day or placebo. In this study, a subgroup of 1,000
en with a creatinine clearance 75 ml/min was identified.
n post hoc analysis, these patients with mild to moderate
KD were found to have a 27% relative risk reduction (0.73
95% CI 0.56 to 0.96]; p  0.02) and a 6.3% ARR in fatal
nd nonfatal MI (28) (Table 4).
Of clinical trials in progress, the SHARP trial is an
ngoing study with a subgroup of 6,000 patients with mild
o moderate CKD (creatinine 1.5 mg/dl). Patients in this
rial with clinical end points will be randomized to simva-
tatin 20 mg/day or simvastatin 20 mg/day plus ezetimibe
0 mg/day. There will be an additional arm in this study
hat includes 3,000 hemodialysis patients (22).
afety Issues in CKD Patients
afety of statin therapy. Although all statins have been
sed safely in patients with CKD (stage 1 and 2), there are
ifferences in statin pharmacokinetic properties that might
onfer safety advantages to some statins (stage 3 to 5). Statin
dverse events are often dose related and related to increased
lood concentrations of the drug. Statins that are more
ependent on renal excretion are more likely to need dose
djustments (Table 5). Atorvastatin has 2% renal excre-
ion and does not require a dose adjustment for GFR 30
ney Disease
End Point
Duration
(Months) Treatment
RRR
95% CI ARR
ath, fatal
NFMI, or
48 Atorvastatin 20 mg/day 8% NA
0.77–1.10
(p  0.37)
ty and
lization
46 Pravastatin 40 mg/day 13% NA
0.49–1.57
(p  0.649)
rtality, major
r event
60 Simvastatin 40 mg/day 28% 11%
(p  0.05)
or
matic NFMI
58.9 Pravastatin 40 mg/day 28% 4%
0.55–0.95
(p  0.02)
ath, NFMI,
procedures
60 Fluvastatin 40–80 mg/day 17% NA
0.64–1.06
(p  0.139)
eath, NFMI 60 Gemfibrozil 1,200 mg/day 27% 6.3%
0.56–0.96
(p  0.02)
vents and 24 n-3 PUFA 1.7 g/day 3% NA
0.72–1.48
(p  0.85)
inine clearance; CV  cardiovascular; GFR  glomerular filtration rate; n-3 PUFA  omega-3
ized controlled trial; RRR  relative risk reduction.ease
c Kid
rimary
iac de
troke,
troke
ortali
ospita
rall mo
ascula
death
ympto
iac de
ardiac
nary d
l CV e
eathl/min/1.73 m2 (29). Also, statins that are metabolized by
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June 24, 2008:2375–84 Treatment of Dyslipidemia in CKDhe cytochrome P450-3A4 system (CYP-3A4) are more
ikely to result in adverse events due to drug–drug interac-
ions. Although fluvastatin and atorvastatin have minimal
xcretion in the kidney, fluvastatin does not use the CYP-
A4 route for metabolism (Table 5) and has no active
irculating metabolites (30,31). In addition, fluvastatin
harmacokinetics are unchanged in patients on hemodialy-
is or on chronic ambulatory peritoneal dialysis (30,31).
Finally, the discovery that statins cause transient mild
ubular proteinuria in some patients has caused some to
uestion their effect on the natural progression of CKD
32). The completion of some of the major clinical trials
lready mentioned (e.g., the SHARP trial) should help to
nswer this question. However, the collective evidence from
ost hoc analysis of large clinical trials with cardiovascular
nd points suggests that statins may preserve renal function
nd reduce proteinuria over time. The Pravastatin Pooling
roject was a post hoc subgroup analysis of data from 3
andomized controlled trials comparing pravastatin 40 mg/
ay to placebo in over 18,000 patients with a prior MI (33).
ravastatin reduced the adjusted rate of kidney function loss
y 8% (0.08 ml/min/1.73 m2/year; 95% CI 0.01 to 0.15)
nd the relative risk of acute renal failure by 60% (95% CI
.41 to 0.86; p  0.005). In a recent meta-analysis, 22
lacebo-controlled trials were identified that studied the
enal benefits of statins. Statins reduced the rate of decline
n GFR by 1.23 ml/min/1.73 m2/year compared with
lacebo. This review, however, was limited by significant
etween-trial heterogeneity (34).
The proposed renal-protective mechanism is based on in
itro observations that statins impede the normal reabsorp-
ion of albumin in the proximal tubule. Mevalonate, a
etabolite in the cholesterol synthetic pathway, is reduced
n patients on statins and is necessary for the normal
eabsorption of albumin in the proximal renal tubule (35).
n vitro studies indicate that protein reabsorption in prox-
mal tubular cells is proinflammatory and contributes to
ubulointersitial disease; therefore, the blocking of protein
eabsorption in tubular cells may be renoprotective over
ime. In summary, although statins may increase tubular
roteinuria initially, they may reduce inflammation, slow
brosis, and result in less proteinuria in the long term (36).
afety of fibric acid derivatives. Fibric acid derivatives,
lso known as fibrates, are peroxisome proliferator activated
linical Pharmacokinetics of Statins
Table 5 Clinical Pharmacokinetics of Statins
Rosuva Atorva Simva Lova Prava Fluva
T 1/2, h 20.8 15–30 2–3 2.9 1.3–2.8 0.5–2.3
Urinary excretion, % 10 2 13 10 20 6
CYP-3A4 metabolism No Yes Yes Yes No No
CYP metabolism 2CY9 3A4 3A4 3A4 sulfation 2CY9
dapted from Blum (31).
Atorva  atorvastatin; CYP  cytochrome P450; CYP-3A4  cytochrome p450-3A4; Fluva 
uvastatin; Lova  lovastatin; Prava  pravastatin; Rosuva  rosuvastatin; Simva  simvastatin;
1/2  half life.eceptor- (PPAR-) agonists and are metabolized in the
Aidney and predominantly eliminated via the renal route
37,38). A characteristic of this class of drugs is their
ropensity to cause a moderate reversible increase in serum
reatinine. Fenofibrate and gemfibrozil are the fibrates
vailable in the U.S. Gemfibrozil is less likely to cause this
ncrease, but is more likely to cause rhabdomyolysis when
ombined with a statin, due to a pharmacokinetic interac-
ion (39). Specifically, gemfibrozil raises statin blood con-
entrations by impairing the glucuronidation of statins,
hereas fenofibrate’s effect on the glucuronidation of statins
s minimal (Table 6) (40). In the FIELD (Fenofibrate
ntervention and Event Lowering in Diabetes) study, over
,700 type II diabetics not taking a statin at baseline were
andomized to micronized fenofibrate 200 mg/day or pla-
ebo and followed for 5 years (41). Plasma creatinine was
losely monitored. During the study, plasma creatinine
emained an average of 0.11 to 0.14 mg/dl higher in the
enofibrate group, which had a median concentration of
.03 at study completion, compared with 0.90 mg/dl in the
lacebo group (p  0.001). Finally, in a subgroup of 661
atients that were studied 8 weeks after ceasing study
edication, the plasma creatinine returned from 1.03 to
.89 mg/dl, suggesting no long-term renal sequelae.
Some have proposed that the fibrate-induced increase in
erum creatinine is due to the reduced production of
asodilatory prostaglandins. Other investigators have sug-
ested that PPAR- agonists increase creatinine production
ithout a reduction in GFR (42). In small retrospective
tudies, gemfibrozil appeared less likely to increase serum
reatinine; however, more recent studies have suggested that
emfibrozil can also cause an increase in creatinine, but to a
maller degree than fenofibrate (43). More importantly,
harmacokinetic studies with gemfibrozil and patients with
KD indicate that the excretion of gemfibrozil is reduced to
lesser extent than fenofibrate (43). Fenofibrate is nondia-
ysable and studies in patients with moderate CKD (GFR
50 ml/min/1.73 m2) demonstrated a reduced rate of
enofibrate excretion and accumulation of the drug with
ersistent usage (38).
Because of these pharmacokinetic characteristics, the
KF and the National Lipid Association (NLA) have
ssued recommendations for the cautious use of fibrates in
atients with CKD (29). The NKF recommends that
tatin/Fibrate Pharmacokinetic Interactions
Table 6 Statin/Fibrate Pharmacokinetic Interactions
Gemfibrozil Fenofibrate
Atorvastatin 1 Cmax by 1.8-fold No effect
Simvastatin 1 Cmax by 2-fold No effect
Pravastatin 1 Cmax by 2-fold No effect
Rosuvastatin 1 Cmax by 2-fold No effect
Fluvastatin No effect No effect
Lovastatin 1 Cmax by 2.8-fold Not available
Cerivastatin 1 Cmax by 2–3-fold No effectdapted from Jacobson and Zimmerman (47).
2  decreases;1  increases; Cmax  maximum concentration.
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Treatment of Dyslipidemia in CKD June 24, 2008:2375–84atients with GFR 60 to 90 ml/min/1.73 m2 should reduce
enofibrate dosing by 50%, those with GFR 15 to 59
l/min/1.73 m2 should reduce dosing by 75%, and those on
emodialysis or with GFR 15 ml/min/1.73 m2 should
ompletely avoid use of fenofibrate. According to the NKF
uidelines, gemfibrozil is designated as the fibrate of choice
n patients with CKD and no dose adjustments are required
or reduction in GFR (29).
The recent NLA guidelines for fenofibrate use are similar
o the NKF guidelines, though they differ in their recom-
endations for gemfibrozil use. The recommended dose of
emfibrozil in CKD patients with GFR 60 ml/min/1.73
2 is 600 mg/day (50% reduction), and it is recommended
o avoid all fibrates for GFR 15 ml/min/1.73 m2. In
ddition, the NLA recommends measuring serum creati-
ine before starting fibrate therapy (39).
Finally, there are concerns about the tendency of fenofi-
rate to also increase already elevated homocysteine levels in
atients with CKD (44). Elevated homocysteine levels are
hought to be a risk factor for vascular disease and hyper-
oagulability. In the FIELD study, plasma homocysteine
as an average of 3.7 mol/l higher in the fenofibrate
roup; however, plasma homocysteine levels were at pre-
tudy baseline within 8 weeks of stopping the fenofibrate
41). Other fenofibrate studies have demonstrated similar
ncreases, whereas studies with other fibrates have not
onsistently demonstrated increases in homocysteine levels
45). The clinical relevance of fenofibrate-induced elevations in
omocysteine is uncertain; however, the FIELD study with
enofibrate and the Coronary Drug Project (46) with clofi-
rate both demonstrated small but significant increases in
enothromboembolic disease in fibrate-treated patients.
afety of statin-fibrate combinations. An additional
afety consideration in patients with CKD is the safety of a
tatin when combined with a fibric acid derivative. Patients
ith CKD frequently have mixed dyslipidemia, and high-
isk patients may need treatment with a statin and a fibric
cid derivative. As discussed in the preceding, there are
istinct pharmacokinetic differences between fibrates when
ombined with statins (Table 6). Gemfibrozil increases the
lasma levels of all of the statins with the exception of
uvastatin, and thus increases the predisposition for rhab-
omyolysis (47). This effect is not seen with fenofibrate and
s not related to cytochrome P450 metabolism, but is due to
he inhibition of the glucuronidation pathway involved in
he metabolism of statins (47). Although gemfibrozil is the
KF fibrate of choice, fenofibrate is the preferred fibrate
ption when combining with a statin. However, both the
tatins and fenofibrate are independently associated with an
ncreased risk of myopathy, and therefore there is increased
isk of myopathy and rhabdomyolysis when these drugs are
ombined. For optimal safety in fibrate-statin combination
reatment, the NLA recommends not using the maximum
ose of a statin in combination with a fibrate (39). afety of other lipid-lowering drugs. The bile acid se-
uestrants, including colesevelam and cholestyramine, are
enerally safe to use in the setting of CKD, because they are
ot systemically absorbed; however, they can increase tri-
lyceride levels and are contraindicated in patients with
levated triglycerides (48). In a recent study, 36 hemodial-
sis patients were treated with colesevelam 1.5 g before
eals for 6 months. Investigators noted a 20% reduction in
on–HDL-C (p  0.0001) and a 63% reduction in median
-reactive protein values (p  0.0259) (49).
There are limited data on the efficacy and safety of
icotinic acid in CKD. Pharmacokinetic studies indicate
hat 34% of the drug is excreted in the kidneys. According
o the NKF guidelines, for those with GFR 15 ml/min/
.73 m2, the dose should be reduced by 50%; otherwise no
osing changes are recommended (29).
There are small studies with ezetimibe indicating that it
s safe and well tolerated in moderate to severe CKD and
hat no modified dosing for reduced GFR is required. In the
K-HARP II (United Kingdom Heart and Renal Protec-
ion II) study, 203 patients with varying degrees of renal
ailure were studied for 6 months (50). Participants included
52 pre-dialysis patients with creatinine levels 1.7 mg/dl,
8 patients on peritoneal dialysis, and 33 patients on
emodialysis. The control group received 20 mg/day sim-
astatin, and the treatment arm was treated with 20 mg
imvastatin plus 10 mg/day ezetimibe. The treatment arm
eceiving 10 mg/day ezetimibe had a 21% greater reduction
n LDL (p  0.0001) than the monotherapy group, yet no
dverse events were experienced with the addition of
zetimibe.
ipid Management in CKD Patients
tages 3 to 4 (GFR 15 to 50 ml/min/1.73 m2)
he NKF and National Cholesterol Education Program
dult Treatment Panel (ATP) III offer similar guidelines
or the management of dyslipidemia in patients with CKD;
owever, significant differences exist (29,51). In the NKF
ecommendations, CKD is regarded as a CHD risk equiv-
lent and an annual lipid panel is recommended. As with
ny dyslipidemic patient, a comprehensive search for sec-
ndary causes of dyslipidemia should be conducted, includ-
ng a search for endocrine disorders such as hypothyroidism
nd diabetes and medications such as corticosteroids, pro-
ease inhibitors, beta-blockers, diuretics, and estrogen.
levated LDL-C. Although patients with CKD fre-
uently have multiple abnormalities in their lipid profile,
DL-C reduction is the primary goal of therapy. The NKF
ecommends LDL-C 100 mg/dl for patients with CKD.
urrently the NKF does not recommend a more aggressive
DL goal for patients with CKD and symptomatic athero-
clerotic disease (30). Based on the amended ATP III
uidelines, it might be prudent to treat to an LDL goal of
70 mg/dl in patients with CKD with atherosclerotic disease.
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June 24, 2008:2375–84 Treatment of Dyslipidemia in CKDs in the general population, statins are the cornerstone of
herapy for dyslipidemia. Treatment with a statin in con-
unction with therapeutic lifestyle changes is usually re-
uired to obtain these goals. All statins can be used safely in
atients with CKD; however, differences in the pharmaco-
inetic properties give some statins a safety advantage in
atients with advanced CKD (GFR 30 ml/min/1.73 m2).
ecause the excretion of atorvastatin in the kidneys is
egligible, no dose adjustment for reduced GFR or hemo-
ialysis is required (Table 7). If combination therapy with a
emfibrozil is likely, then fluvastatin may be the safest
hoice. Other statins require dose adjustments as CKD
ecomes more advanced (30) (Table 7).
In patients not at their LDL goal on atorvastatin or
uvastatin, ezetimibe or bile acid sequestrants can be added
afely (Table 8). Bile acid sequestrants’ safety may be limited
osing Modifications for Lipid-Lowering Drugs in CKD
Table 7 Dosing Modifications for Lipid-Lowering Drugs in CKD
Agent
GFR 60–90
ml/min/1.73 m2
GFR 15–59
ml/min/1.73 m2
GFR <
ml/min/1
Statins
Atorvastatin No No No
Fluvastatin No Not defined Not de
Lovastatin No 2 to 50% 2 to
Pravastatin No No No
Rosuvastatin No 5–10 mg 5–10
Simvastatin No No 5 m
Nonstatins
Nicotinic acid No No 2 to
Cholestyramine No No No
Colesevelam No No No
Ezetimibe No No No
Fenofibrate 2 to 50% 2 to 25% Avo
Gemfibrozil No No No
Omega-3 FAs No No No
dapted from the K/DOQI clinical practice guidelines (29).
2  decrease;1  increase; CKD  chronic kidney disease; FA  fatty acid; GFR  glomeru
roposed Treatment Algorithm for Lipid Management in Patients W
Table 8 Proposed Treatment Algorithm for Lipid Management i
Lipid Disorder
Moderate to severe CKD, stages 3 to 4 (GFR 15–59 ml/min/1.73 m2)
Elevated LDL-C 1
2
Mixed dyslipidemia* (not at non-HDL† goal) 1
2
3
4
Very high triglycerides (triglyceride 500 mg/dl) 1
2
3
CKD stage 5 (hemodialysis or GFR 15 ml/min/1.73 m2)
Elevated LDL-C A
Mixed dyslipidemia A
Very high triglycerides OMixed dyslipidemia  elevated triglycerides and low HDL with or without elevated LDL. †Non-HDL  to
CKD  chronic kidney disease; GFR  glomerular filtration rate; HDL  high-density lipoprotein; LDL-Cy their tendency to increase triglycerides, which frequently
re elevated in CKD. In addition, bile acid sequestrants may
e limited by their tendency to bind to other medications
nd reduce their absorption (48).
ixed dyslipidemia. Most patients with CKD have tri-
lyceride as well as HDL abnormalities along with elevated
DL (mixed dyslipidemia). After LDL goal attainment,
on-HDL should be the primary goal in the management
f patients with CKD with mixed dyslipidemia. Non-HDL
s the only lipid measurement that correlates positively with
ardiovascular mortality in hemodialysis patients (52). Very-
ow-density lipoprotein and intermediate-density lipopro-
ein are both known to be elevated in patients with CKD
ith mixed dyslipidemia, and therefore non-HDL may be a
etter marker of atherogenic cholesterol levels. Based on
KF recommendations, patients with CKD should be
2 Notes
2 dose to one-half at GFR 30 ml/min/1.73 m2
2 dose to one-half at GFR 30 ml/min/1.73 m2
Start at 10 mg/day for GFR 60 ml/min/1.73 m2
Start at 5 mg/day for GFR 30 ml/min/1.73 m2, max dose 10 mg/day
Start at 5 mg if GFR 10 ml/min/1.73 m2
34% kidney excretion
Not absorbed
Not absorbed
May1 serum creatinine
NLA recommends a dose of 600 mg/day for GFR 15–59 ml/min/1.73 m2
and avoiding use for GFR 15 ml/min/1.73 m2
tion rate; NLA  National Lipid Association.
KD (Stage 3 to 5)
ients With CKD (Stage 3 to 5)
Therapeutic Option (See Table 7 for Dose Adjustments)
vastatin, add ezetimibe if not at LDL-C goal
astatin, add ezetimibe if not at LDL-C goal
vastatin or fluvastatin  ezetimibe
astatin  gemfibrozil 600 mg/day  ezetimibe if not at non-HDL goal
in  omega-3 fatty acids, add ezetimibe if not at non-HDL goal
in  fenofibrate 48 mg/day, add ezetimibe if not at non-HDL goal
fibrozil 600 mg/day
ga-3 fatty acids 3–4 g/day
ofibrate 48 mg/day
tatin (10–80 mg/day) or fluvastatin 40 mg/day, add ezetimibe if not at LDL-C goal
tatin or fluvastatin 40 mg/day, add ezetimibe 10 mg/day or omega-3 fatty acids
g/day if not at non-HDL goal
3 fatty acids 3–4 g/day or gemfibrozil 600 mg/day15
.73 m
fined
50%
mg
g
50%
idith C
n Pat
) Ator
) Fluv
) Ator
) Fluv
) Stat
) Stat
) Gem
) Ome
) Fen
torvas
torvas
3–4
mega-tal cholesterol  HDL cholesterol.
 low-density lipoprotein cholesterol.
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130 mg/dl (30).
Patients with mixed dyslipidemia frequently require com-
ination therapy with a statin plus additional lipid-lowering
rugs that could include ezetimibe, a fibrate, niacin, or
mega-3 fatty acids. Although ezetimibe has a negligible
ffect on HDL and triglycerides, the addition of ezetimibe
o a statin results in a significant additional reduction in
on–HDL-C, which is the secondary therapeutic goal in
ixed dyslipidemia (Table 8). The combination of
zetimibe and a statin is relatively safe and well tolerated in
atients with CKD (50).
The omega-3 fatty acids may also be used in combination
ith a statin. Although published data on this combination
n patients with CKD is limited, omega-3 fatty acids do not
ave significant interactions with statins and do not require
ose reductions for impaired renal function (53).
Although fibrates can be used to treat mixed dyslipide-
ia, they need to be used carefully, because they are
redominantly metabolized by the kidneys. According to
he NKF guidelines, gemfibrozil is the fibrate of choice in
atients with CKD (29). There is still controversy concern-
ng the safety of fenofibrate in patients with CKD, because
f its propensity for increasing serum creatinine and homo-
ysteine to a greater degree than gemfibrozil. Due to the
ncreased risk of rhabdomyolysis with fibrate and statin
herapy in patients with CKD, the combination requires
ore vigilant monitoring, and patients need to report
uscle symptoms immediately. Combined with a statin,
enofibrate clearly has advantages due to its lack of phar-
acokinetic interactions with statins and lower propensity
or rhabdomyolysis (47). When gemfibrozil is selected for
ombination treatment with a statin, consideration should
e given to changing the statin to fluvastatin, for which
here is no pharmacokinetic interaction and fewer cases of
habdomyolysis have been reported compared with other
tatins. Because of fluvastatin’s lower efficacy in LDL
eduction, the addition of a third drug, ezetimibe, may be
ecessary (Table 8). Because CKD alone is a risk factor for
habdomyolysis, the combination of a statin with any fibrate
till needs to be weighed carefully from a risk-benefit
erspective.
Niacin is also an option for the treatment of mixed
yslipidemia. Niacin has been shown to increase HDL-C,
nd reduce both lipoprotein (a) and triglycerides, which are
levated in patients with CKD, but its use is limited due to
oor tolerability (50). The NKF clinical practice guidelines
ecommend reducing niacin dosing by 50% for GFR 15
g/ml/1.73 m2. Bile acid sequestrants are usually not an
ption in mixed hyperlipidemia, due to their tendency to
ncrease triglycerides (29).
ery high triglycerides (>500 mg/dl). The first goal for
atients with fasting triglycerides 500 mg/dl is to prevent
ancreatitis (51). Fibrates are frequently started in this
cenario, because they are better tolerated than niacin and
re more efficacious triglyceride-lowering drugs than the ttatins. Currently, because of safety concerns, gemfibrozil
ould be recommended over fenofibrate (Table 8). Al-
hough some studies suggest that the dose of gemfibrozil
oes not need to be reduced in severe renal failure, the NLA
afety Task Force on Lipid-Lowering Drugs recommends
hat the gemfibrozil dose should be reduced to 600 mg/day
or patients with a GFR 60 ml/min/1.73 m2 and avoided
n patients with a GFR 15 ml/min/1.73 m2 (39). Finally,
f fenofibrate must be used, the dose should not exceed 48
g/day and creatinine levels should be monitored care-
ully (39).
Another option for very high triglycerides is to treat with
mega-3 fatty acids derived from fish oil. The main active
ngredients in fish oil are eicosapentaenoic acid (EPA) and
ocosahexaenoic (DHA). Four grams of omega-3 fatty
cids per day, in the form of fish oil capsules, have been
hown to reduce triglycerides 35% to 45% (54). The
mega-3 fatty acids are safe in patients with CKD and have
inimal drug interactions. Until recently, a major limitation
as that over-the-counter preparations had only 200 to 300
g omega-3 fatty acids per capsule, requiring the consump-
ion of 12 to 16 capsules/day. The only available
rescription-brand omega-3 fatty acid contains almost 900
g omega-3 fatty acids, requiring only 4 capsules/day (54).
ipid Management in Hemodialysis Patients
CKD Stage 5; GFR <15 ml/min/1.73 m2)
he options for hemodialysis CKD stage 5 patients are
ore limited than patients with CKD stages 1 through 4.
or patients with elevated LDL-C, choosing statins with
imited renal excretion, such as atorvastatin or fluvastatin,
ay be more important (Table 8). In mixed dyslipidemia,
mega-3 fatty acids may have a more prominent role,
ecause the NLA recommends avoiding fibrate use in
atients with a GFR 15 ml/min/1.73 m2 (39). In patients
ith very high triglycerides, clinicians can treat with 3 to 4
/day omega-3 fatty acids, or if a fibrate must be used then
emfibrozil can be given at a reduced dose of 600 mg/day.
onclusions
he incidence of CKD in the U.S. continues to increase,
nd now over 10% of the U.S. population has some form of
KD. These patients have markedly increased risk
f cardiovascular events and death. Because patients with
KD are at high risk, the NKF has designated CKD a
HD risk equivalent, and studies suggest that CKD is as
owerful a risk factor as diabetes mellitus (8). Although
any factors other than lipids may contribute to the high
ardiovascular event rates observed in patients with CKD, it
s likely that dyslipidemia plays a major role. Early epide-
iologic studies suggesting that high cholesterol was an
dvantage for hemodialysis patients were most likely con-
ounded. The severe derangements seen in lipoprotein
etabolism in patients with CKD typically results in highriglycerides and low HDL-C.
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June 24, 2008:2375–84 Treatment of Dyslipidemia in CKDStatins are the cornerstone of therapy for most patients
ith CKD, except those with triglycerides 500 mg/dl, in
hich case gemfibrozil or an omega-3 fatty acid supplement
rom fish oil could be considered. Because of the high
revalence of triglyceride disorders in patients with CKD,
on-HDL should be calculated for patients with CKD and
sed as the secondary goal of treatment.
Evidence from subgroup analysis of several landmark
ipid trials supports treating dyslipidemia in mild to mod-
rate patients with CKD, and this group represents the
ajority of patients with CKD. Currently there is no
vidence to support treating hemodialysis patients; however,
large trials using statins with hemodialysis patients are
nderway. Because statins are relatively safe and the evi-
ence for lowering cholesterol to reduce CVD is so over-
helmingly positive in nonhemodialysis patients, it is rea-
onable to continue treating these patients until future trials
re completed.
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